mani
posit
attribut
dna
vaccin
make
conceptu
desir
platform
clinic
studi
howev
standard
dna
inject
alon
gener
induc
low
level
transgenespecif
immun
compar
vaccin
approach
order
boost
immunogen
platform
nextgener
dna
vaccin
requir
addit
techniqu
administr
electropor
new
method
involv
gener
brief
electr
field
tissu
around
local
inject
site
result
transient
porat
permeabil
cellular
membran
result
antigenspecif
immun
respons
greatli
enhanc
like
due
increas
dna
uptak
antigen
express
thu
electroporationmedi
dna
vaccin
repres
promis
new
strategi
elicit
strong
immun
respons
direct
express
antigen
vector
ongo
studi
current
underway
optim
work
paramet
techniqu
review
use
technolog
conjunct
vaccin
suggest
futur
direct
explor
discourag
result
recent
human
hiv
trial
perform
merck
collabor
name
step
rais
seriou
question
current
vaccin
approach
use
replicationdefect
viral
vector
studi
intern
phase
ii
test
concept
trial
uninfect
volunt
high
risk
acquir
hiv
infect
show
vaccin
use
recombin
adenoviru
serotyp
vector
ineffect
prevent
viru
infect
even
increas
rate
transmiss
individu
exhibit
prior
immun
viral
vector
vaccin
safe
immunogen
human
nonhuman
primat
elicit
longlast
multifunct
cell
respons
partial
protect
rhesu
macaqu
discoveri
vaccin
could
possibl
heighten
hiv
infect
unexpect
alarm
result
immedi
discontinu
vaccin
recommend
independ
data
safeti
monitor
board
step
sinc
preexist
immun
vaccin
vector
may
compromis
efficaci
human
futur
vaccin
approach
aim
util
vector
exhibit
minim
reactiv
immunocompet
vaccin
dna
vaccin
consist
administr
genet
materi
encod
desir
antigen
express
vaccin
capabl
elicit
immun
respons
compar
approach
advantag
dna
vaccin
mani
infecti
agent
involv
vaccin
unabl
revert
virul
form
like
live
vaccin
prime
cytotox
humor
respons
dna
vector
easili
manipul
test
rapidli
produc
high
yield
bacteria
readili
isol
also
temperaturest
convent
vaccin
easili
store
transport
requir
cold
chain
furthermor
dna
vaccin
could
potenti
induc
immun
newborn
situat
usual
neutral
convent
vaccin
via
presenc
high
level
matern
antibodi
introduct
exogen
dna
cell
tissu
achiev
use
dna
conjug
virusderiv
vector
nake
plasmid
dna
pdna
nake
pdna
show
variabl
low
transfect
efficaci
administ
convent
mean
needl
inject
topic
applic
howev
sever
strategi
aim
improv
pdna
vaccin
immunogen
develop
includ
codon
optim
mrna
optim
addit
leader
sequenc
construct
consensu
immunogen
strategi
help
boost
overal
immunogen
dna
vaccin
may
applic
antigen
recent
electropor
electropermeabil
gain
great
interest
multipl
research
area
includ
gene
therapi
vaccinolog
although
precis
mechan
action
yet
well
defin
hypothes
cell
membran
host
tissu
receiv
electropor
normal
imperm
charg
molecul
form
pore
function
equival
structur
chang
upon
applic
extern
electr
field
facilit
influx
macromolecul
thu
higher
transfect
efficaci
nake
pdna
result
electropor
thought
major
contributor
increas
immunogen
electroporationmedi
dna
vaccin
addit
shown
electropor
increas
vaccin
potenc
activ
antigenpres
cell
apc
via
danger
signal
local
inflamm
recruit
immun
cell
site
dna
administr
furthermor
direct
transfect
apc
could
also
facilit
electropor
current
intens
investig
focus
upon
util
electropor
muscl
skin
effect
method
dna
vaccin
deliveri
small
larg
anim
human
safeti
feasibl
electropor
human
recent
demonstr
final
proven
thu
paramount
question
dna
vaccin
time
whether
suffici
level
efficaci
reach
present
methodolog
improv
breakthrough
vaccin
design
andor
electropor
deliveri
necessari
first
transgen
express
detect
skelet
muscl
inject
nake
mrna
pdna
rais
possibl
use
method
certain
gene
therapi
dna
vaccin
subsequ
transgen
express
also
obtain
way
wide
varieti
tissu
transgen
express
gener
low
variabl
use
envis
purpos
attempt
suffici
enhanc
pdna
uptak
thu
transgen
express
cation
lipid
gene
gun
also
proven
unsuccess
date
first
public
substanti
increas
transgen
express
electropor
appli
vivo
pdna
inject
appear
late
although
electropor
use
vitro
cell
transfect
sinc
addit
point
bettan
et
al
use
gene
electrotransf
higher
interindividu
reproduc
gene
transduct
observ
skelet
muscl
fig
frequent
target
tissu
gene
therapi
dna
vaccin
studi
either
without
electropor
reason
muscl
cell
also
known
myocyt
muscl
tissu
continu
attract
target
transgen
express
includ
muscl
tissu
easili
access
plenti
well
vascular
latter
facilit
circul
antigen
produc
transfect
muscl
cell
discuss
gene
electrotransf
muscl
found
chap
vivo
electropor
use
deliv
dna
vaccin
encod
antigen
numer
infecti
agent
summar
tabl
enhanc
immun
respons
electroporationmedi
dna
vaccin
observ
small
larg
anim
mice
pig
monkey
widera
et
al
demonstr
mice
upon
electropor
treatment
deliveri
weakli
immunogen
hepat
b
viru
hbv
surfac
antigen
hb
ag
dna
vaccin
result
increas
humor
immun
respons
character
rapid
onset
higher
titer
antihb
ag
antibodi
addit
author
observ
studi
potenc
hiv
gag
pdna
vaccin
increas
shown
lower
dosag
dna
requir
induc
higher
antigenspecif
antibodi
level
increas
cell
respons
similarli
studi
carri
bovin
herp
truncat
glycoprotein
dna
vaccin
tsang
et
al
show
onset
primari
humor
respons
earlier
group
treat
dna
follow
electropor
group
produc
higher
antibodi
level
group
receiv
im
dna
immun
recombin
protein
vaccin
similar
result
obtain
earlier
otherwis
inert
microparticul
adjuv
interestingli
effici
transfect
electropor
increas
doubl
dose
dna
administ
howev
durat
antigenspecif
antibodi
respons
increas
higher
rate
comparison
immun
dose
plasmid
without
electropor
moreov
electropor
increas
degre
consist
among
individu
dnapluselectropor
group
seen
week
followup
final
high
correl
durat
primari
immun
respons
magnitud
secondari
antibodi
respons
observ
impli
electropor
could
repres
effect
approach
elicit
longer
memori
antibodi
respons
capon
et
al
demonstr
gene
electrotransf
effici
increas
cellular
immun
respons
mice
rhesu
macaqu
vaccin
plasmid
encod
nonstructur
region
hepat
c
viru
hcv
particular
show
ex
vivo
interferon
ifn
g
elispot
assay
electropor
mice
induc
fivefold
potent
cell
respons
dna
administr
alon
elicit
respons
direct
six
antigen
pool
span
hcv
region
assess
whether
electropor
treatment
elicit
similar
respons
nonhuman
primat
model
immun
rhesu
macaqu
three
time
vaccin
collect
peripher
blood
mononuclear
cell
period
interv
test
cell
effector
function
immun
respons
observ
electroporationtr
group
show
faster
kinet
anim
respond
second
challeng
reach
peak
third
moreov
anim
treat
electropor
show
cell
respons
comparison
nake
dna
group
show
weaker
respons
respons
final
gene
electrotransferimmun
macaqu
maintain
antihcv
effector
cell
entir
observ
period
month
indic
gene
electrotransf
effici
elicit
strong
memori
cell
respons
dna
vaccin
associ
electropor
repres
effect
strategi
elicit
strong
broad
longlast
b
cell
respons
although
muscl
common
target
dna
vaccin
immun
presenc
apc
skin
layer
make
attract
target
nucleic
acid
vaccin
sinc
direct
transfect
apc
may
import
cell
prime
upon
skin
dna
immun
fig
murin
model
use
viral
demonstr
singl
intraderm
id
inject
without
electropor
nake
dna
encod
influenza
nucleoprotein
gene
suffici
induc
product
antigenspecif
antibodi
cytotox
lymphocyt
persist
least
week
protect
lethal
challeng
heterolog
strain
influenza
viru
furthermor
immun
respons
id
dna
vaccin
record
significantli
enhanc
vivo
electropor
analysi
antibodi
respons
hb
agencod
plasmid
deliv
id
upon
electropor
mice
reveal
strong
enhanc
h
respons
mainli
character
strong
cellmedi
respons
compar
elicit
protein
immun
show
exclus
h
pattern
character
domin
humor
respons
also
nonhuman
primat
model
studi
carri
rhesu
macaqu
idpluselectropor
group
develop
ifngproduc
cell
twice
memori
cell
group
treat
electropor
higher
antibodi
respons
record
idpluselectropor
group
compar
impluselectropor
group
altogeth
result
support
idea
electropor
follow
dna
inject
muscl
skin
repres
effect
approach
larg
anim
immun
sever
author
hypothes
inflamm
caus
electropor
import
prime
immun
respons
dna
vaccin
local
inflamm
previous
propos
augment
immun
respons
studi
pdna
coinject
bupivicainehcl
local
tissu
damag
induc
electr
field
thought
recruit
cell
increas
number
infiltr
immun
cell
inject
site
inde
electropor
caus
activ
proinflammatori
signal
includ
express
chemokin
liu
et
al
character
extent
natur
cellular
infiltr
site
electropor
vaccin
deliveri
mice
found
polymorphonuclear
mononuclear
cell
local
perivascular
space
throughout
muscl
tissu
particular
observ
signific
increas
b
cell
cell
dramat
increas
macrophag
dendrit
cell
compar
vaccin
alon
differ
howev
record
among
cell
popul
blood
spleen
drain
lymph
node
mice
treat
without
electropor
suggest
local
factor
involv
augment
immun
respons
follow
electropor
also
author
observ
cell
infiltr
transient
resolv
within
week
thu
improv
antigen
present
may
repres
one
mechan
electropor
may
elicit
potent
immun
respons
typic
innat
immun
recognit
adjuv
compon
vaccin
formul
shown
critic
immunogen
mani
adjuv
ligand
tolllik
receptor
tlr
like
monophosphoryl
lipid
cpg
dna
convent
adjuv
aluminum
hydroxid
incomplet
freud
adjuv
free
tlr
ligand
therefor
exampl
demonstr
multipl
innat
immun
recognit
signal
pathway
requir
adjuv
function
case
dna
vaccin
controversi
main
vaccin
compon
contribut
induct
innat
adapt
immun
respons
cpg
motif
express
within
plasmid
backbon
stimul
innat
immun
tlr
induct
adapt
immun
respons
unaffect
absenc
innat
receptor
howev
recent
shown
doublestrand
structur
dna
independ
cpg
sequenc
possess
immunomodulatori
effect
administ
intracellularli
trigger
tlrindepend
tankbind
kinas
inf
regulatori
factor
innat
activ
immun
nonimmun
cell
produc
type
inf
induc
gene
recent
ishii
et
al
report
enhanc
dna
vaccin
immunogen
achiev
electropor
may
due
increas
transfect
rate
result
techniqu
better
contribut
local
inflamm
activ
cell
produc
ifn
signal
pathway
data
suggest
key
signal
molecul
dna
vaccin
immunogen
regul
innat
immun
signal
critic
induct
adapt
immun
respons
enhanc
immunogen
pdna
electropor
may
result
pdna
interact
intracellular
accord
hypothesi
peng
et
al
postul
local
inflamm
import
actual
quantiti
express
transgen
determin
magnitud
immun
respons
demonstr
higher
antibodi
titer
cell
prolifer
rate
observ
appli
electr
puls
day
prior
im
dna
immun
case
postul
increas
crosspresent
direct
transfect
infiltr
apc
result
increas
local
inflamm
may
contribut
augment
immun
respons
electroporationmedi
dna
vaccin
appear
mechan
electropor
enhanc
respons
nake
plasmid
vaccin
increas
dna
transfect
possibl
includ
local
inflamm
may
augment
magnitud
durat
transgen
express
inde
babiuk
et
al
observ
highest
level
lymphocyt
infiltr
muscl
tissu
treat
electropor
elicit
higher
level
transgen
express
expect
consid
antigen
product
critic
retent
cellular
infiltr
site
local
inflamm
although
two
dna
vaccin
recent
approv
usa
canada
vaccin
hors
west
nile
viru
salmon
infecti
hematopoiet
necrosi
viru
dna
vaccin
approv
use
human
howev
encourag
result
preclin
trial
use
electropor
technolog
dna
vaccin
larg
anim
model
prompt
much
interest
techniqu
safeti
current
toler
human
demonstr
healthi
volunt
antidna
antibodi
detect
patient
electropor
muscl
dna
inject
integr
pdna
host
chromosom
follow
electroporationmedi
deliveri
observ
togeth
result
suffici
regulatori
approv
sever
clinic
trial
report
clinicaltrialsgov
seven
electrotransf
dna
vaccin
trial
cancer
three
clinic
trial
use
dna
vaccin
infecti
agent
associ
electropor
current
open
ongo
clinic
studi
use
electroporationmedi
dna
vaccin
infecti
agent
includ
three
phase
studi
involv
muscl
electropor
first
test
safeti
immunolog
effect
pennvax
b
hiv
vaccin
encod
gag
pol
env
hivinfect
individu
vgx
pharmaceut
inc
second
assess
safeti
toler
immunogen
human
papillomaviru
hpv
dna
plasmid
deliv
electropor
adult
femal
postsurg
abl
treatment
grade
cervic
intraepitheli
neoplasia
vgx
pharmaceut
inc
third
one
phase
iii
trial
test
toler
efficaci
imadminist
chronvacc
combin
electropor
chronic
hcv
genotyp
infect
patient
low
viral
load
tripep
ab
amount
pain
distress
associ
electropor
human
toler
level
anticip
benefit
date
electroporationmedi
dna
vaccin
human
perform
administr
inject
volum
ml
follow
short
ms
low
electr
field
strength
vcm
puls
puls
given
condit
effici
dna
vaccin
larg
anim
nonhuman
primat
suffici
human
electropor
result
sharp
quick
pain
compar
receiv
short
electr
shock
sensat
transient
administr
shortact
sed
drug
painkil
treatment
consid
accordingli
report
daud
et
al
clinic
trial
use
plasmid
deliv
electropor
patient
metastat
melanoma
order
limit
patient
discomfort
lidocain
either
administ
topic
inject
around
tumor
site
intraven
analges
andor
anxiolyt
drug
offer
patient
electropor
notabl
previou
studi
shown
pain
limit
factor
patient
discomfort
limit
period
electr
stimul
subject
usual
return
repeat
treatment
without
ask
sedat
also
muscl
electropor
like
muscl
inject
mild
ach
may
experienc
site
electropor
day
similar
follow
strenuou
workout
sever
factor
determin
strength
pain
associ
electropor
although
high
interindividu
variabl
percept
pain
among
factor
number
length
space
thick
electrod
needl
primarili
electr
puls
paramet
dictat
pain
threshold
exclus
criteria
electropor
treatment
may
includ
presenc
metal
implant
near
site
electr
deliveri
presenc
pacemak
case
muscl
electropor
obes
sinc
treatment
efficaci
may
decreas
muscl
tissu
reach
vaccin
electr
puls
deliveri
electroporationmedi
dna
vaccin
deliveri
requir
puls
gener
control
paramet
individu
puls
puls
train
amplitud
durat
number
polar
wave
form
frequenc
electrod
usual
integr
applic
electrod
direct
contact
subject
treat
geometri
shape
size
distanc
ultim
determin
shape
strength
electr
field
electr
current
target
tissu
fig
thu
properti
puls
electrod
respons
desir
enhanc
dna
deliveri
well
undesir
side
effect
proper
design
puls
electrod
maxim
effect
given
dna
vaccin
minim
unwant
side
effect
longlast
histolog
chang
pain
muscl
contract
discuss
electropor
paramet
equip
found
chap
skin
potenti
interest
target
tissu
dna
vaccin
natur
role
immun
defens
bodi
readi
access
discuss
gene
electrotransf
dna
gener
skin
found
chap
respect
goal
vaccin
strategi
prime
broad
longlast
immun
respons
capabl
robust
effector
respons
upon
antigen
restimul
protect
infecti
agent
minim
toxic
vaccin
sinc
complic
may
aris
due
use
viralbas
vector
preexist
immun
regul
vaccin
effect
possibl
revers
virul
may
decreas
vaccin
efficaci
safeti
altern
approach
explor
futur
vaccin
approach
dna
vaccin
appear
even
attract
candid
futur
vaccin
sinc
safe
immunogen
stimul
vectorspecif
immun
extens
literatur
support
hypothesi
electropor
repres
valid
approach
vaccin
administr
increas
consist
potenc
vaccin
induc
higher
level
antibodymedi
cytotox
cell
respons
way
electropor
may
help
augment
transloc
exogen
dna
nucleu
furthermor
proven
effect
enhanc
immun
respons
antigen
regardless
degre
transgen
express
achiev
recent
evid
suggest
innat
immun
recognit
adjuv
compon
vaccin
danger
signal
provid
method
vaccin
may
import
determin
magnitud
result
immun
respons
electropor
may
enhanc
local
inflamm
site
immun
facilit
transfect
greater
amount
pdna
may
readili
avail
interact
intracellular
signal
protein
trigger
secret
inflammatori
cytokin
needletyp
electrod
consist
variabl
number
primarili
stainless
steel
needl
arrang
differ
configur
pictur
depict
array
fire
rotat
chord
pattern
array
fire
oppos
pair
cross
triangular
pattern
array
fire
pin
pin
induc
gene
electroporationmedi
dna
vaccin
current
topic
intens
research
theoret
studi
practic
trial
requir
optim
deliveri
vaccin
target
tissu
electr
paramet
facilit
dna
uptak
calibr
local
tissu
damag
reduc
pain
associ
vaccin
deliveri
electropor
